Century Therapeutics revenue was $109.16M for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2025) ending on Dec 31, 2025 was $0.0, down N/A from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, IPSC annual revenue was $109.2M, with 1,556.8% growth year-over-year.
IPSC past revenue growth
How has IPSC's revenue growth performed historically?
On Invalid Date, Century Therapeutics (NASDAQ: IPSC) reported Q4 2025 revenue of $0.00 up 100% year over year. In the same quarter last year, Century Therapeutics's revenue was $4.17 million.
What was Century Therapeutics's revenue in 2025?
Century Therapeutics's annual revenue for the twelve months ending Dec 31, 2025 was $109.16 million, a 1,556.76% increase year over year.
How much does Century Therapeutics make in a day?
Based on Century Therapeutics annual revenue for the past five years, IPSC makes an average of $67,499.73 per day.
What was Century Therapeutics's annual revenue growth in the past year?
As of Q1 2026, Century Therapeutics's revenue has grown 1,556.76% year over year. This is 1,088.53 percentage points higher than the US Biotechnology industry revenue growth rate of 468.23%. Century Therapeutics's revenue in the past year totaled $109.16 million.
How much does Century Therapeutics make in a year?
Century Therapeutics's revenue by year for the past five years is:
Century Therapeutics's revenue for the twelve months ending Dec 31, 2025 was $109.16 million, a 1,556.76% increase year over year.
Century Therapeutics's annual revenue for Dec 31, 2024 was $6.59 million, a 194.81% increase from 2023.
Century Therapeutics's annual revenue for 2023 was $2.24 million, a 57.01% decrease from 2022.
Century Therapeutics's annual revenue for 2022 was $5.20 million, a Infinity% increase from 2021.
Century Therapeutics's annual revenue for 2021 was $0.00, a N/A decrease from 2020.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.